BridgeBio Pharma Revenue 2018-2024 | BBIO
BridgeBio Pharma annual/quarterly revenue history and growth rate from 2018 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- BridgeBio Pharma revenue for the quarter ending September 30, 2024 was $0.003B, a 33.22% decline year-over-year.
- BridgeBio Pharma revenue for the twelve months ending September 30, 2024 was $0.218B, a 2209.77% increase year-over-year.
- BridgeBio Pharma annual revenue for 2023 was $0.009B, a 88.02% decline from 2022.
- BridgeBio Pharma annual revenue for 2022 was $0.078B, a 11.38% increase from 2021.
- BridgeBio Pharma annual revenue for 2021 was $0.07B, a 745.14% increase from 2020.
BridgeBio Pharma Annual Revenue
(Millions of US $) |
| 2023 |
$9 |
| 2022 |
$78 |
| 2021 |
$70 |
| 2020 |
$8 |
| 2019 |
$41 |
| 2018 |
$ |
| 2017 |
$ |
BridgeBio Pharma Quarterly Revenue
(Millions of US $) |
| 2024-09-30 |
$3 |
| 2024-06-30 |
$2 |
| 2024-03-31 |
$211 |
| 2023-12-31 |
$2 |
| 2023-09-30 |
$4 |
| 2023-06-30 |
$2 |
| 2023-03-31 |
$2 |
| 2022-12-31 |
$2 |
| 2022-09-30 |
$0 |
| 2022-06-30 |
$74 |
| 2022-03-31 |
$2 |
| 2021-12-31 |
$13 |
| 2021-09-30 |
$2 |
| 2021-06-30 |
$54 |
| 2021-03-31 |
$0 |
| 2020-12-31 |
$0 |
| 2020-09-30 |
$8 |
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
$14 |
| 2019-09-30 |
$27 |
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$6.773B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
